SLP
Get informed when a big investor buys or sells
+ FollowUndervalued by 53.4% based on the discounted cash flow analysis.
| Market cap | $345.72 Million |
|---|---|
| Enterprise Value | $326.70 Million |
| Dividend Yield | $0.24 (-) |
| Earnings per Share | $-3.22 |
| Beta | 1.28 |
| Outstanding Shares | 20,150,000 |
| P/E Ratio | -5.49 |
|---|---|
| PEG | -11.55 |
| Price to Sales | 5.55 |
| Price to Book Ratio | 2.78 |
| Enterprise Value to Revenue | 4.06 |
| Enterprise Value to EBIT | -2.29 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0660▲ 6.60% |
|---|---|
| Total Calls | 200,000▲ 619.42% |
| Total Puts | 13,200▲ Infinity% |
Holdings and activity of institutional investors.
| Ownership % | 80.08%▲ 0.18% |
|---|---|
| Total Invested | $191.10M▼ 34.87% |
| Investors Holding | 159▼ 11.00% |
No data
Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With its subsidiaries, Cognigen, DILIsym Services, and...